Key Highlights

  • EyePoint Pharmaceuticals' Phase 3 LUGANO trial for DURAVYU missed the primary BCVA endpoint in the full dataset.
  • Ad hoc exclusion of 9 unrelated vision-loss patients showed non-inferiority to aflibercept.
  • Secondary endpoints demonstrated 42% lower treatment burden and strong supplement-free rates.
  • Approval prospects now depend on Q4 2026 LUCIA data and a planned H1 2027 NDA.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) reported that its Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration missed the primary best-corrected visual acuity endpoint in the full dataset.

What Happened

Ad hoc exclusion of 9 unrelated vision-loss patients showed non-inferiority to aflibercept, and secondary endpoints demonstrated 42% lower treatment burden, strong supplement-free rates, and a favorable safety profile.

Approval prospects are now dependent on Q4 2026 LUCIA data and a planned NDA submission in the first half of 2027.

Market Reaction

The disclosed information does not include stock price or trading data for EyePoint Pharmaceuticals following the trial results.

Outlook

Q4 2026 LUCIA data represents the next major disclosed milestone for DURAVYU in wet AMD, ahead of the company's planned NDA submission in the first half of 2027.